Tokushima University / Educator and Researcher Directory --- Yamaguchi, Sumiyo

Search:

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Kazuyoshi Okada, Manabu Tashiro, Sumiyo Yamaguchi, Tomoko Inoue, Takahiro Kuragano and Jun Minakuchi : Lower mortality in calcimimetic users compared to non-users in dialysis patients with serum parathyroid hormone levels within the target range., Scientific Reports, 16, 1, 2025. (Summary) Lower serum parathyroid hormone (PTH) levels are reported to improve mortality and fracture incidence in patients using calcimimetics. We investigated the prognosis of calcimimetic users and non-users with similar PTH levels within the target range. This retrospective study compared 2-year all-cause mortality and the incidence of any fracture in dialysis patients between calcimimetic users (n = 131) and non-users (n = 294) with PTH levels between 60 and 240 pg/mL using a propensity score-matched model. Kaplan-Meier survival curves censored by PTH level, calcimimetic use, and other factors were compared; then, adjusted Cox proportional hazards regression analysis was performed. After matching, mortality was significantly lower in calcimimetic users than in non-users (n = 130; hazard ratio [HR] 0.243, 95% confidence interval [CI] 0.073-0.801, P = 0.022, log-rank test). The PTH levels of users and non-users were 142.4 ± 49.4 and 132.7 ± 48.0 pg/mL, respectively (P = 0.127). Cox regression analysis demonstrated that mortality was significantly lower in users than in non-users (adjusted HR 0.260, 95% CI 0.071-0.947, P = 0.041). Calcimimetic use had no effect on fracture incidence. These findings suggest that, among dialysis patients with PTH levels between 60 and 240 pg/mL, mortality risk was significantly lower among calcimimetic users than in non-users. However, fracture risk was not significantly different between these groups. (Keyword) Humans / Parathyroid Hormone / Female / Male / Renal Dialysis / Middle Aged / Retrospective Studies / Calcimimetic Agents / Aged / Fractures, Bone / Proportional Hazards Models / Kaplan-Meier Estimate / Incidence / Kidney Failure, Chronic / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-025-29458-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41318745 ● Search Scopus @ Elsevier (PMID): 41318745 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-025-29458-5 (DOI: 10.1038/s41598-025-29458-5, PubMed: 41318745)
2.	Kazuyoshi Okada, Manabu Tashiro, Hiroyuki Michiwaki, Sumiyo Yamaguchi, Tomoko Inoue, Takahiro Kuragano and Jun Minakuchi : Improved survival with high albumin leakage in patients with protein-energy wasting and inflammation on hemodialysis and online hemodiafiltration., Scientific Reports, 15, 1, 2025. (Summary) Albumin leakage (Alb-L) and serum albumin (S-Alb) levels are predictors of mortality in dialysis patients. Because protein-energy wasting (PEW) and inflammation reduce hepatic albumin synthesis, we hypothesized that mortality would differ based on Alb-L and/or S-Alb levels, depending on the presence of PEW and inflammation. This retrospective study included 738 super high-flux hemodialysis (SHF HD) and online hemodiafiltration (OHDF) patients. Three-year all-cause mortality was compared in patients without PEW and inflammation (Group 1) and with PEW and/or inflammation (Group 2) using a propensity score matching model and Cox regression analysis with adjustment. In Group 2, mortality in patients with "high Alb-L" or "high S-Alb" was significantly lower in comparison to low groups, but not in Group 1. In Group 2, mortality in the "high Alb-L" and "high S-Alb (3.5 ± 0.2 g/dL)" group was lower than in other groups, including Group 1, except for the "high Alb-L" and "low S-Alb (3.2 ± 0.2 g/dL)" group, which had no deaths. In SHF HD and OHDF patients with PEW and/or inflammation, "high Alb-L" with normoalbuminemia to mild hypoalbuminemia improved survival to a level similar to patients without PEW and inflammation. Additionally, Alb-L and/or S-Alb had little impact on mortality in patients without PEW and inflammation. (Keyword) Humans / Male / Female / Inflammation / Hemodiafiltration / Renal Dialysis / Middle Aged / Aged / Retrospective Studies / Serum Albumin / Protein-Energy Malnutrition / Kidney Failure, Chronic (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-025-07047-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40751051 ● Search Scopus @ Elsevier (PMID): 40751051 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-025-07047-w (DOI: 10.1038/s41598-025-07047-w, PubMed: 40751051)
3.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada and Shu Wakino : Ability of NAD and Sirt1 to epigenetically suppress albuminuria., Clinical and Experimental Nephrology, 28, 7, 599-607, 2024. (Summary) The time for diabetic nephropathy (DN) to progress from mild to severe is long. Thus, methods to continuously repress DN are required to exert long-lasting effects mediated through epigenetic regulation. In this study, we demonstrated the ability of nicotinamide adenine dinucleotide (NAD) and its metabolites to reduce albuminuria through Sirt1- or Nampt-dependent epigenetic regulation. We previously reported that proximal tubular Sirt1 was lowered before glomerular Sirt1. Repressed glomerular Sirt1 was found to epigenetically elevate Claudin-1. In addition, we reported that proximal tubular Nampt deficiency epigenetically augmented TIMP-1 levels in Sirt6-mediated pathways, leading to type-IV collagen deposition and diabetic fibrosis. Altogether, we propose that the Sirt1/Claudin-1 axis may be crucial in the onset of albuminuria at the early stages of DN and that the Nampt/Sirt6/TIMP-1 axis promotes diabetic fibrosis in the middle to late stages of DN. Finally, administration of NMN, an NAD precursor, epigenetically potentiates the regression of the onset of DN to maintain Sirt1 and repress Claudin-1 in podocytes, suggesting the potential use of NAD metabolites as epigenetic medications for DN. (Keyword) Animals / Humans / Albuminuria / Claudin-1 / cytokinesis / Diabetic Nephropathies / Epigenesis, Genetic / Fibrosis / Kidney Tubules, Proximal / Mice, Inbred C57BL / knockout mice / NAD / Nicotinamide Mononucleotide / Nicotinamide Phosphoribosyltransferase / Podocytes / Sirtuin 1 / Sirtuins / Tissue Inhibitor of Metalloproteinase-1 (Tokushima University Institutional Repository) ● Metadata: 2012209 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10157-024-02502-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38587753 ● Summary page in Scopus @ Elsevier: 2-s2.0-85189697626 ● Summary page in Scopus @ Elsevier: 2-s2.0-85196749614 (Tokushima University Institutional Repository: 2012209, DOI: 10.1007/s10157-024-02502-w, PubMed: 38587753, Elsevier: Scopus, Elsevier: Scopus)
4.	Sumiyo Yamaguchi, Shingen Nakamura, 住田智志, 前田悠作, Masahiro Oura, 高橋真美子, 岩佐昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Jun Kishi and Masahiro Abe : Development of adult T-cell leukemia/lymphoma during immunosuppressive Therapy for human T-cell leukemia virus type 1 associated arthropathy, Shikoku Acta Medica, 73, 5,6, 301-308, 2017. (Summary) A 64-year-old woman presented with lower leg edema, fever, and bilateral joint pain, involving the wrists, fingers, and knees, in April 201X. Serological test results were negative for rheumatoid factor, antinuclear antibody, and anti-cyclic citrullinated peptide antibody. A diagnosis of remitting seronegative symmetrical synovitis with pitting edema syndrome, a type of seronegative rheumatoid arthritis, was made and prednisolone was administered. The joint pain was refractory to prednisolone therapy. In February, 201X+2, the patient presented with right cervical lymphadenopathy. The CT scan revealed swelling of the cervical, axillary, and inguinal lymph nodes bilaterally and rapidly enlarged. In April, 18F-fluorodeoxyglucose PET/CT scan showed an abnormal collection in the enlarged lymph nodes. The patient subsequently developed hoarseness with dyspnea and attended our department. Blood test results showed high levels of lactate dehydrogenase (547U/L) and soluble interleukin‐2 receptor (34200 IU/L) and were positive for anti-human T-cell leukemia virus type1 (HTLV‐1) antibody. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells positive for CD3, CD4, and CD25 and negative for CD7. Monoclonal integration of HTLV‐1 proviral DNA was detected in the lymph node. A diagnosis of adult T-cell leukemia/lymphoma (ATLL), lymphoma type was made. The pain involving multiple joints was attributed to HTLV‐1associated arthropathy. Immunosuppressive therapy for HTLV‐1 carrier status may have played a role in the development of ATLL. (Keyword) Adult T-cell leukemia/lymphoma / HTLV-1 / rheumatoid arthritis / immunosuppressive therapy (Tokushima University Institutional Repository) ● Metadata: 2005223 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050022708922062464 (Tokushima University Institutional Repository: 2005223, CiNii: 1050022708922062464)

Review, Commentary:

1.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Masanori Minato, Taizo Inagaki, 清水郁子, Sumiyo Yamaguchi, 宮上慎司, 多田美穂 and Shu Wakino : 特集糖尿病性腎症研究の最前線糖尿病性腎症の発症機序糖尿病性腎症におけるミトコンドリアの役割, Kidney and Dialysis, 96, 2, 159-164, Feb. 2024. (Tokushima University Institutional Repository) ● Metadata: 2012211 (Link to Publication Site) ● Publication site (DOI): 10.24479/kd.0000001187 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390299528381041664 ● Search Scopus @ Elsevier (DOI): 10.24479/kd.0000001187 (Tokushima University Institutional Repository: 2012211, DOI: 10.24479/kd.0000001187, CiNii: 1390299528381041664)

Proceeding of Domestic Conference:

1.	Sumiyo Yamaguchi, Taizo Inagaki, 沖成千尋, 平田彩乃, 多田美穂, Masanori Minato, Eriko Shibata, Masanori Tamaki, Kazuhiro Hasegawa and Shu Wakino : マルチキナーゼ阻害薬投与によりlupus like nephrotisを発症した1例, 第131回日本内科学会四国地方会, Dec. 2024.
2.	宮上慎司, Masanori Tamaki, Miho Tada, Sumiyo Yamaguchi and Shu Wakino : ステロイドとリツキシマブが奏功したキャッスルマン病合併HIV関連免疫複合体腎臓病の一例, Japanese Journal of Nephrology, 65, 6-W, 744, Sep. 2023.
3.	Sumiyo Yamaguchi, Masanori Tamaki, 宮上慎司, Eriko Shibata and Shu Wakino : アンモニア除去に苦慮した55歳発症尿素サイクル異常症の1例, Journal of Japanese Society for Dialysis Therapy, 56, Suppl.1, 431, May 2023.
4.	Masanori Tamaki, 宮上慎司, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : ロキサデュスタット投与後に奇異性脳塞栓を発症した1例, Japanese Journal of Nephrology, 64, 6-W, 719, Oct. 2022.
5.	宮上慎司, Masanori Tamaki, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : コロナウィルスワクチン後発症した悪性腎硬化症の一例, Japanese Journal of Nephrology, 64, 6-W, 719, Oct. 2022.
6.	Sayo Ueda, Eriko Shibata, Masanori Tamaki, Masanori Minato, 岩城真帆, Ikuko Shimizu, Sumiyo Yamaguchi, 宮上慎司, Kazuhiro Hasegawa and Shu Wakino : 急性間質性腎炎を認めた敗血症性AKIの症例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 507, May 2022.
7.	Masanori Tamaki, 宮上慎司, 岩城真帆, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kojiro Nagai, Kazuhiro Hasegawa and Shu Wakino : 腹膜透析導入後に膵癌を発症した1例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 631, May 2022.
8.	Ikuko Shimizu, Masanori Tamaki, 宮上慎司, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : 慢性大動脈解離に伴う慢性DICのため腎代替療法導入に苦慮した1例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 663, May 2022.
9.	Masanori Tamaki, 宮上慎司, 岩城真帆, 清水郁子, Sumiyo Yamaguchi, 湊将典, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa, Kojiro Nagai and Shu Wakino : 膵癌を合併した腹膜透析患者の1例, 第27回日本腹膜透析医学会学術集会・総会, Oct. 2021.
10.	Sumiyo Yamaguchi, Masanori Tamaki, Ikuko Shimizu, Shinji Miyakami, Masanori Minato, Sayo Ueda, Eriko Shibata, Kojiro Nagai and Shu Wakino : ペメトレキセドによる尿細管間質性腎炎の一例, 第51回日本腎臓学会西部学術集会, Oct. 2021.
11.	宮上慎司, Masanori Tamaki, Kenji Nishimura, 岩城真帆, 清水郁子, Sumiyo Yamaguchi, Sayo Ueda, Eriko Shibata, Hideharu Abe, Kojiro Nagai and Shu Wakino : 繰り返す菌血症に対し予防的抗菌薬投与が奏功した1例, Journal of Japanese Society for Dialysis Therapy, Jun. 2021.
12.	Sumiyo Yamaguchi, Kenji Nishimura, 岩城真帆, Ikuko Shimizu, Sayo Ueda, Eriko Shibata, Masanori Tamaki, Hideharu Abe and Kojiro Nagai : ネフローゼ症候群の加療中に腰背部痛，発熱で発症し，DIC傾向を呈した成人水痘の一例, 第50回日本腎臓学会西部学術集会, 676, Oct. 2020.
13.	Sumiyo Yamaguchi, 岩城真帆, 清水郁子, 稲垣太造, 湊将典, Hiroyuki Ono, Sayo Ueda, Kenji Nishimura, Eriko Shibata, Masanori Tamaki, Kojiro Nagai and Hideharu Abe : 全身倦怠感，呼吸困難感を生じ，その後急性高Ca血症と判明した透析患者の一例, 第47回徳島透析療法研究会, Nov. 2019.
14.	清水郁子, Kojiro Nagai, 稲垣太造, 湊将典, 岩城真帆, Sumiyo Yamaguchi, Sayo Ueda, Kenji Nishimura, Hiroyuki Ono, Eriko Shibata, Masanori Tamaki, Fumi Kishi, Taichi Murakami, Seiji Kishi and Hideharu Abe : 慢性B型肝炎治療中に緩徐に進行する腎機能障害をみとめた一例, 第49回日本腎臓学会西部学術大会, Oct. 2019.
15.	Sumiyo Yamaguchi, 岩城真帆, 清水郁子, 稲垣太造, 湊将典, Hiroyuki Ono, Sayo Ueda, Kenji Nishimura, Eriko Shibata, Masanori Tamaki, Kojiro Nagai, Masuda shiho, Itsuro Endo and Hideharu Abe : 透析導入期に急性高Ca血症を生じた一例, 第49回日本腎臓学会西部学術大会, Oct. 2019.
16.	黒澤すみれ, 清水郁子, 稲垣太造, 湊将典, 岩城真帆, Sumiyo Yamaguchi, 上田紗代, Kenji Nishimura, Hiroyuki Ono, Eriko Shibata, Masanori Tamaki, Hideharu Abe, 早渕修 and Kojiro Nagai : B型肝炎治療薬によって緩徐に腎機能悪化をみとめた一例, 第259回徳島医学会学術集会, Aug. 2019.

Et cetera, Workshop:

1.	Masanori Tamaki, 湊将典, 宮上慎司, 岩城真帆, 清水郁子, Sumiyo Yamaguchi, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : ステントグラフト留置術がAVG頻回閉塞に有用であった一例, 第55回四国透析療法研究会, Oct. 2021.
2.	遠藤理子, 宮上慎司, 湊将典, Masanori Tamaki, 岩城真帆, 清水郁子, Sumiyo Yamaguchi, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : 膜性腎症に合併したIgG4関連腎臓病の一例, 第263回徳島医学会, Aug. 2021.